
Insulet Corporation
- Jurisdiction
United States - LEI
549300TZTYD2PYN92D43 - ISIN
US45784P1012 (PODD )- Sectors
Scores
- Fair value (Benjamin Graham formula)
-
€132.19 103.6% overvalued - Financial strength (Piotroski F-Value)
-
6
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
6
/ 7
Profile
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. Read full profile
Fundamentals
- Net revenue
€1.87B - Gross margin
76.3% - EBIT
€347.41M - EBIT margin
18.6% - Net income
€201.38M - Net margin
10.8%
Statement period: - (published )
Estimates
Fiscal Year | Net revenue | Net income |
---|---|---|
|
| |
|
| |
|
|
Stock price
Dividends
No dividend payouts
Analyst ratings
No analyst ratings available
Insider Transactions
Name | Title | Transaction Date | Shares | Price | Value |
---|---|---|---|---|---|
Benjamin Eric | EVP, CPXO |
|
|
|
|
Singh Prem | SVP, Global Operations |
|
|
|
|
Investor transactions
Name | Shares | Value | Last change | Change type |
---|---|---|---|---|
James Anderson |
|
|
|
Sell |
Peter Brown |
|
|
|
Buy |
Ray Dalio |
|
|
|
Sell |